NORFOLK, Va.–ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the...
Read MoreData confirm elevated inflammatory biomarkers in newborns with Hypoxic Ischemic Encephalopathy (HIE) and demonstrate a predictable pharmacokinetic profile for RLS-0071...
Read MoreNORFOLK, Va.–ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the...
Read MoreNORFOLK, Va.–ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the...
Read MoreNORFOLK, Va. – February 25, 2025 – ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated...
Read MoreData demonstrates pegtarazimod’s ability to reduce inflammation and significantly increase survival rates in multiple preclinical models of aGVHD Norfolk, Va...
Read MoreNorfolk, VA, November 21, 2024 – ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to...
Read MoreNorfolk, VA, November 5, 2024 – ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to...
Read MoreCompany is advancing three Phase 2 clinical programs evaluating RLS-0071 in rare and acute inflammatory diseases with limited treatment options...
Read More